TL;DR
This paper reports the first case of EML4-NTRK3 fusion cervical sarcoma from China and reviews existing literature to better understand this rare cancer. The findings highlight the diagnostic challenges, current treatment approaches (surgery and emerging TRK inhibitors), and suggest age and mitotic rate as potential prognostic factors for recurrence.
What Problem Does This Paper Address?
NTRK gene fusions, while rare in common cancers, are increasingly recognized as drivers in various tumor types. However, NTRK fusion cervical and uterine tumors are exceptionally rare, making their recognition and effective treatment challenging. Clinicians often rely on individual case reports, leading to a fragmented understanding of their clinicopathological features, optimal treatment strategies, and prognostic indicators. This paper aims to address this knowledge gap by presenting a novel case and synthesizing existing literature to provide a more comprehensive overview of NTRK fusion cervical and uterine sarcomas.
Methods
The study employed a multi-faceted approach:
- Case Report: A detailed account of a 33-year-old woman diagnosed with EML4-NTRK3 fusion cervical sarcoma is presented, including her clinical presentation, diagnostic workup (imaging, histopathology, immunohistochemistry - IHC), treatment, and outcome.
- Literature Review: A systematic search of Chinese and international databases (CNKI, PubMed, MEDLINE) was conducted to identify reported cases of NTRK fusion cervical or uterine tumors.
- Clinicopathological Summary: Data from the literature review were compiled to summarize features such as clinical presentation, histological characteristics, immunophenotype, treatment modalities, and prognosis.
- Survival Analysis: Univariate survival analysis using SPSS software was performed on available prognostic data from the reviewed cases to identify factors associated with tumor recurrence or metastasis.
Datasets
The study utilized data from:
- A single patient case: This forms the core of the case report.
- Published literature: A total of 11 articles comprising 23 previously reported cases of NTRK fusion cervical or uterine tumors were included in the literature review.
Key Insights and Ideas
- Diagnostic Complexity: NTRK fusion cervical sarcomas are notoriously difficult to diagnose, often requiring advanced molecular pathology techniques beyond standard IHC. Morphological features can mimic other rare tumors, necessitating a high index of suspicion and comprehensive testing.
- Emerging Therapeutic Promise: While surgery remains the cornerstone of treatment, the advent of TRK inhibitors (like larotrectinib and entrectinib) offers a significant new avenue for patients with NTRK fusion-driven cancers, particularly those with metastatic disease.
- Prognostic Clues: Age (≥ 35 years) and a high mitotic count (>10/10 HPFs) were identified as potential indicators of increased risk for tumor recurrence or metastasis in this rare cancer.
- Need for Centralized Data: The rarity of these tumors underscores the critical need for an international database to aggregate sporadic cases, enabling more robust research and the development of standardized diagnostic and treatment guidelines.
Key Results
- The study reported the first case of EML4-NTRK3 fusion cervical sarcoma diagnosed in a Chinese institution.
- The literature review identified 19 cases of NTRK fusion cervical tumors and 4 cases of uterine tumors.
- TPM3-NTRK1 was the most common fusion type observed in the reviewed cases.
- Univariate survival analysis indicated that age ≥ 35 years (P=0.016) and a mitotic count > 10/10 HPFs (P=0.009) were statistically associated with tumor recurrence or metastasis.
- The patient in the case report experienced rapid disease progression, including brain and lung metastases, and unfortunately passed away 14 months after diagnosis, highlighting the aggressive nature of some NTRK fusion sarcomas and the current limitations in treatment accessibility (especially TRK inhibitors in certain regions).
Limitations and Future Work
The authors acknowledge several limitations:
- Data Dispersion: The rarity of these tumors makes it challenging to obtain complete patient data.
- Small Cohort Size: The univariate survival analysis, while suggestive, is limited by the small number of cases, necessitating larger studies for confirmation.
- Lack of Unified Guidelines: The absence of standardized diagnostic and treatment guidelines for NTRK fusion cervical/uterine sarcomas hinders research and clinical practice.
Future work should focus on:
- Establishing an International Database: Aggregating data from rare cases is crucial for more definitive conclusions.
- Exploring Novel Biomarkers: Further research is needed to identify reliable tumor markers for sarcoma, potentially including exosomes.
- Investigating Treatment Efficacy: Continued clinical trials and real-world data collection are essential to optimize the use of TRK inhibitors and other therapeutic strategies.
- Standardizing Staging: Developing a unified staging method for cervical sarcoma would improve comparability across studies.
- Ovarian Preservation: Further investigation is needed to determine the feasibility and safety of ovarian preservation in NTRK fusion cervical/uterine sarcomas.
Summary updated